Gan & Lee Pharmaceuticals Co Ltd (603087) — Net Asset Quality Index
Gan & Lee Pharmaceuticals Co Ltd (603087) has a Net Asset Quality Index of 93.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥12.68 Billion minus total liabilities of CN¥851.65 Million yields net assets of CN¥11.83 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Gan & Lee Pharmaceuticals Co Ltd (603087) defensive interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Gan & Lee Pharmaceuticals Co Ltd Net Asset Quality Index Over Time (2013–2025)
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 93.3%, representing net assets of CN¥11.83 Billion against total assets of CN¥12.68 Billion CNY. Explore Gan & Lee Pharmaceuticals Co Ltd (603087) cash conversion ratio to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is Gan & Lee Pharmaceuticals Co Ltd worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 92.1% | CN¥11.63 Billion | CN¥12.63 Billion | CN¥998.57 Million | ▲ +0.3 pp |
| 2024 | 91.8% | CN¥11.05 Billion | CN¥12.04 Billion | CN¥988.45 Million | ▲ +0.1 pp |
| 2023 | 91.7% | CN¥10.74 Billion | CN¥11.72 Billion | CN¥972.52 Million | ▲ +1.3 pp |
| 2022 | 90.4% | CN¥9.59 Billion | CN¥10.61 Billion | CN¥1.02 Billion | ▼ -3.3 pp |
| 2021 | 93.7% | CN¥10.17 Billion | CN¥10.85 Billion | CN¥686.02 Million | ▼ -0.3 pp |
| 2020 | 94.0% | CN¥8.94 Billion | CN¥9.51 Billion | CN¥569.09 Million | ▲ +3.2 pp |
| 2019 | 90.8% | CN¥5.47 Billion | CN¥6.03 Billion | CN¥555.88 Million | ▼ -0.2 pp |
| 2018 | 91.0% | CN¥4.27 Billion | CN¥4.69 Billion | CN¥424.18 Million | ▲ +1.9 pp |
| 2017 | 89.1% | CN¥3.34 Billion | CN¥3.74 Billion | CN¥408.00 Million | ▲ +2.5 pp |
| 2016 | 86.6% | CN¥2.26 Billion | CN¥2.60 Billion | CN¥348.06 Million | ▲ +4.6 pp |
| 2015 | 82.0% | CN¥1.49 Billion | CN¥1.81 Billion | CN¥325.41 Million | ▼ -4.3 pp |
| 2014 | 86.3% | CN¥1.04 Billion | CN¥1.20 Billion | CN¥164.18 Million | ▼ -1.7 pp |
| 2013 | 88.1% | CN¥733.22 Million | CN¥832.55 Million | CN¥99.33 Million | — |